Former Lilly Exec To Lead HHS, a Flurry of FDA Approvals, & Gates Bets $100M on Alzheimer’s

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.